RAPP insider filings
Rapport Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-03. Screen RAPP transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 15 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 11 legs across 7 filings by 7 insiders — 1,031,174 shares, $22,023,904 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 14 legs across 7 filings by 3 insiders — 96,233 shares, $4,470,180 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
- Largest priced transaction: purchase of 952,380 shares @ $21.00 ($19,999,980) by HEALY JAMES, filed 2026-10-30.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| HEALY JAMES — Director | 1 | 4 legs · 969,480 sh · $20,359,080 | — | — |
| Yeleswaram Krishnaswamy — Chief Development Officer | 1 | — | 3 legs · 50,160 sh · $2,531,582 | — |
| Ceesay Abraham — Chief Executive Officer, Director | 5 | — | 9 legs · 36,073 sh · $1,606,741 | — |
| PAUL STEVEN M — Director | 1 | 1 leg · 35,714 sh · $974,278 | — | — |
| Gault Cheryl — Chief Operating Officer | 1 | — | 2 legs · 10,000 sh · $331,856 | — |
| MARAGANORE JOHN — Director | 1 | 2 legs · 9,411 sh · $248,891 | — | — |
| Ignelzi Troy A. — Chief Financial Officer | 1 | 1 leg · 5,500 sh · $143,550 | — | — |
| Young Wendy B. — Director | 1 | 1 leg · 3,789 sh · $99,992 | — | — |
| Silva Paul M — Director | 1 | 1 leg · 3,680 sh · $99,636 | — | — |
| Sanchez Ramiro — Director | 1 | 1 leg · 3,600 sh · $98,478 | — | — |
+1 more insider in the window, not shown — every filing appears in the table below.
Recent insider filings — Rapport Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-03 | 4 | Third Rock Ventures V, L.P. — Director, 10% owner Third Rock Ventures GP V, LP — Director, 10% owner TRV GP V, LLC — Director, 10% owner Third Rock Ventures VI, L.P. — Director, 10% owner Third Rock Ventures GP VI, L.P. — Director, 10% owner TRV GP VI, LLC — Director, 10% owner | Grant/award (A): 238,095 @ $21 · Grant/award (A): 1,190,476 @ $21 | EDGAR |
| 2026-10-30 | 4 | HEALY JAMES — Director | Purchase (P): 952,380 @ $21 · Purchase (P): 6,395 @ $21 · Purchase (P): 3,772 @ $21 · Purchase (P): 6,933 @ $21 | EDGAR |
| 2026-10-23 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 2,210 @ $29.16 | EDGAR |
| 2026-10-23 | 4 | Sanchez Ramiro — Director | Purchase (P): 3,600 @ $27.35 | EDGAR |
| 2026-10-22 | 4 | Young Wendy B. — Director | Purchase (P): 3,789 @ $26.39 | EDGAR |
| 2026-10-22 | 4 | Silva Paul M — Director | Purchase (P): 3,680 @ $27.07 | EDGAR |
| 2026-10-22 | 4 | MARAGANORE JOHN — Director | Purchase (P): 8,239 @ $26.38 · Purchase (P): 1,172 @ $26.92 | EDGAR |
| 2026-10-22 | 4 | PAUL STEVEN M — Director | Purchase (P): 35,714 @ $27.28 | EDGAR |
| 2026-10-21 | 4 | Ignelzi Troy A. — Chief Financial Officer | Purchase (P): 5,500 @ $26.10 | EDGAR |
| 2026-10-08 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 3,375 @ $32.03 · Sale (S): 1,147 @ $30.66 | EDGAR |
| 2026-10-01 | 4 | Gault Cheryl — Chief Operating Officer | Sale (S): 7,925 @ $33.04 · Sale (S): 2,075 @ $33.76 | EDGAR |
| 2026-09-24 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 1,952 @ $39.05 · Sale (S): 215 @ $39.86 · Sale (S): 43 @ $41.05 | EDGAR |
| 2026-09-09 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 7,141 @ $45.55 · Sale (S): 1,069 @ $46.01 | EDGAR |
| 2026-08-26 | 4 | Yeleswaram Krishnaswamy — Chief Development Officer | Sale (S): 13,160 @ $50.00 · Sale (S): 20,799 @ $50.31 · Sale (S): 16,201 @ $51.06 | EDGAR |
| 2026-08-26 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 18,921 @ $49.57 | EDGAR |
| 2026-08-20 | 4 | Yeleswaram Krishnaswamy — Chief Development Officer | Sale (S): 404 @ $49.90 | EDGAR |
| 2026-08-12 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 14,171 @ $45.97 · Sale (S): 8,370 @ $46.75 · Sale (S): 3,664 @ $46.90 · Sale (S): 19,500 @ $48.04 · Sale (S): 5,794 @ $48.62 | EDGAR |
| 2026-07-29 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 2,203 @ $42.11 · Sale (S): 7 @ $42.73 | EDGAR |
| 2026-07-15 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 5,481 @ $39.72 · Sale (S): 2,729 @ $40.57 | EDGAR |
| 2026-07-01 | 4 | Gault Cheryl — Chief Operating Officer | Sale (S): 1,900 @ $40.09 · Sale (S): 3,792 @ $41.39 · Sale (S): 3,308 @ $42.17 · Sale (S): 1,000 @ $43.15 | EDGAR |
| 2026-07-01 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 7,344 @ $39.77 · Sale (S): 876 @ $40.34 | EDGAR |
| 2026-06-10 | 4 | Young Wendy B. — Director | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Sanchez Ramiro — Director | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Huber Reid M — Director | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Silva Paul M — Director | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | PEREZ ROBERT J — Director | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | HEALY JAMES — Director | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | PAUL STEVEN M — Director | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | MARAGANORE JOHN — Director | Grant/award (A): 15,200 (derivative) @ $0 | EDGAR |
| 2026-05-28 | 4 | Third Rock Ventures V, L.P. — 10% owner Third Rock Ventures GP V, LP — 10% owner TRV GP V, LLC — 10% owner Third Rock Ventures VI, L.P. — 10% owner Third Rock Ventures GP VI, L.P. — 10% owner TRV GP VI, LLC — 10% owner | Sale (S): 18,572 @ $40.05 | EDGAR |
| 2026-05-13 | 4 | Third Rock Ventures V, L.P. — 10% owner Third Rock Ventures GP V, LP — 10% owner TRV GP V, LLC — 10% owner Third Rock Ventures VI, L.P. — 10% owner Third Rock Ventures GP VI, L.P. — 10% owner TRV GP VI, LLC — 10% owner | Sale (S): 133,618 @ $40.24 | EDGAR |
| 2026-05-11 | 4 | Third Rock Ventures V, L.P. — 10% owner Third Rock Ventures GP V, LP — 10% owner TRV GP V, LLC — 10% owner Third Rock Ventures VI, L.P. — 10% owner Third Rock Ventures GP VI, L.P. — 10% owner TRV GP VI, LLC — 10% owner | Sale (S): 271,495 @ $40.12 · Sale (S): 5,018 @ $40.31 | EDGAR |
| 2026-04-21 | 4 | Yeleswaram Krishnaswamy — Chief Development Officer | Sale (S): 20,225 @ $39.99 | EDGAR |
| 2026-04-21 | 4 | Third Rock Ventures V, L.P. — 10% owner Third Rock Ventures GP V, LP — 10% owner TRV GP V, LLC — 10% owner Third Rock Ventures VI, L.P. — 10% owner Third Rock Ventures GP VI, L.P. — 10% owner TRV GP VI, LLC — 10% owner | Sale (S): 426,005 @ $40.32 | EDGAR |
| 2026-04-14 | 4 | Yeleswaram Krishnaswamy — Chief Development Officer | Sale (S): 500 @ $34.98 · Sale (S): 9,165 @ $34.97 · Sale (S): 10,200 @ $35.08 | EDGAR |
| 2026-04-09 | 4 | Yeleswaram Krishnaswamy — Chief Development Officer | Sale (S): 360 @ $34.90 | EDGAR |
| 2026-03-31 | 4 | Gault Cheryl — Chief Operating Officer | Sale (S): 7,161 @ $28.04 · Sale (S): 2,839 @ $28.55 | EDGAR |
| 2026-03-26 | 4 | Yeleswaram Krishnaswamy — Chief Development Officer | Sale (S): 10,115 @ $29.99 | EDGAR |
| 2026-03-09 | 4 | Gault Cheryl — Chief Operating Officer | Sale (S): 2,014 @ $28.93 | EDGAR |
| 2026-02-19 | 4 | Bredt David — Chief Scientific Officer | Sale (S): 900 @ $28.02 · Sale (S): 5,400 @ $28.95 · Sale (S): 2,200 @ $29.59 · Option exercise (M): 6,000 @ $1.80 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 3,552 @ $29.05 · Sale (S): 2,281 @ $29.80 · Sale (S): 2,983 @ $29.04 · Sale (S): 2,100 @ $29.80 | EDGAR |
| 2026-02-04 | 4 | Yeleswaram Krishnaswamy — Chief Development Officer | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Bredt David — Chief Scientific Officer | Grant/award (A): 103,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Gault Cheryl — Chief Operating Officer | Grant/award (A): 132,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Sevigny Jeffrey — Chief Medical Officer | Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Grant/award (A): 428,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Ignelzi Troy A. — Chief Financial Officer | Grant/award (A): 148,000 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | Ceesay Abraham — Chief Executive Officer, Director | Sale (S): 5,833 @ $26.12 · Sale (S): 5,083 @ $26.11 | EDGAR |
| 2026-01-16 | 4 | Bredt David — Chief Scientific Officer | Sale (S): 8,300 @ $26.83 · Sale (S): 200 @ $27.40 | EDGAR |
| 2026-01-05 | 4 | Yeleswaram Krishnaswamy — Chief Development Officer | Grant/award (A): 9,000 · Sale (S): 2,840 @ $30.05 | EDGAR |
Recent 8-K events — Rapport Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-20 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-21 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events | EDGAR |
| 2026-03-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
GET https://api.filingpulse.io/v1/insider-trades?ticker=RAPP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs